Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
3 hedge funds and large institutions have $3.61M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
491% more capital invested
Capital invested by funds: $611K → $3.61M (+$3M)
200% more funds holding
Funds holding: 1 → 3 (+2)
9.29% more ownership
Funds ownership: 2.29% → 11.59% (+9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$3M |
| 2 |
SAM
Shikiar Asset Management
New York
|
+$1.04M |
| 3 |
PCG
Private Capital Group
West Hartford,
Connecticut
|
+$1.41K |
Top Sellers
FBIOP Hedge Fund Activity: Q1 2020 in Review
3 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q1 2020, worth a combined $3.61M — up 491% from $611K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new FBIOP positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Uniplan Investment Counsel, opening a new position worth an estimated $3M.
- 3 institutional investors held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q1 2020, up from 1 in Q4 2019.
- Funds reported $3.61M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q1 2020, up 491% quarter-over-quarter.
- 2 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q1 2020 and 0 closed out, a net change of +2 holders.
- The largest Fortress Biotech 9.375% Series A Preferred Stock buyer in Q1 2020 was Uniplan Investment Counsel, an estimated $3M added.
Based on aggregated 13F filings for Q1 2020.